EICHOR
● Completed
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Condition: Colorectal Cancer (CRC) · Sponsor: Amgen
About this study
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (105)
| Central Alabama Research | Birmingham, Alabama, United States | — |
| City of Hope National Medical Center | Duarte, California, United States | — |
| University of California Irvine | Orange, California, United States | — |
| Johns Hopkins University School of Medicine | Washington D.C., District of Columbia, United States | — |
| Cancer Specialists of North Florida | Jacksonville, Florida, United States | — |
| Lakes Research LLC | Miami Lakes, Florida, United States | — |
| Northwest Georgia Oncology Centers PC | Marietta, Georgia, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| Revive Research Institute | Farmington Hills, Michigan, United States | — |
| Sparrow Clinical Research Institute | Lansing, Michigan, United States | — |
| Revive Research Institute | Sterling Heights, Michigan, United States | — |
| Upstate University Hospital | Syracuse, New York, United States | — |
+ 93 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05198934